TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TMS Co., Ltd. ( (JP:4891) ) has provided an announcement.
TMS Co., Ltd. announced the first data readout from its Phase I clinical trial of TMS-008, which showed good safety and tolerability in healthy adult male subjects. TMS-008, part of the SMTP compound family, has strong anti-inflammatory and antioxidant properties and is being developed as a potential treatment for acute kidney injury. While the trial results will not impact the company’s current financial year, they are expected to enhance mid-to-long-term business performance.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformative medicines for serious diseases with high unmet medical needs. The company focuses on a pipeline of small molecule compounds known as SMTPs, derived from a fungus, and has programs targeting conditions such as acute ischemic stroke, resistant hypertension, acute kidney injury, and spinal cord injury.
YTD Price Performance: -34.86%
Average Trading Volume: 1,863,122
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen5.73B
For a thorough assessment of 4891 stock, go to TipRanks’ Stock Analysis page.